These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20407947)

  • 1. A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF.
    Caffrey RE
    Methods Mol Biol; 2010; 641():167-83. PubMed ID: 20407947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads.
    Deng B; Dong Z; Liu Y; Wang C; Liu J; Wang C; Qu X
    Clin Chim Acta; 2010 Aug; 411(15-16):1051-7. PubMed ID: 20361951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling of urine using ProteinChip® technology.
    Woodbury RL; McCarthy DL; Bulman AL
    Methods Mol Biol; 2012; 818():97-107. PubMed ID: 22083818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
    O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
    Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices.
    Poon TC
    Expert Rev Proteomics; 2007 Feb; 4(1):51-65. PubMed ID: 17288515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
    Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
    Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker discovery in serum/plasma using surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry.
    Ndao M
    Methods Mol Biol; 2012; 818():67-79. PubMed ID: 22083816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capillary electrophoresis coupled to mass spectrometry for proteomic profiling of human urine and biomarker discovery.
    Zürbig P; Schiffer E; Mischak H
    Methods Mol Biol; 2009; 564():105-21. PubMed ID: 19544019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.
    Park Y; Downing SR; Kim D; Hahn WC; Li C; Kantoff PW; Wei LJ
    Bioinformatics; 2007 Jun; 23(12):1451-8. PubMed ID: 17459967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lucid Proteomics System for top-down biomarker research.
    Jourdain S; Bulman A; Dalmasso E
    Arch Physiol Biochem; 2010; 116(4-5):158-62. PubMed ID: 20507259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
    Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods.
    Johnston O; Cassidy H; O'Connell S; O'Riordan A; Gallagher W; Maguire PB; Wynne K; Cagney G; Ryan MP; Conlon PJ; McMorrow T
    Proteomics Clin Appl; 2011 Aug; 5(7-8):422-31. PubMed ID: 21751411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
    Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
    J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-source decay causes artifacts in SELDI-TOF MS spectra.
    Ekblad L; Baldetorp B; Fernö M; Olsson H; Bratt C
    J Proteome Res; 2007 Apr; 6(4):1609-14. PubMed ID: 17373843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data processing and analysis using ProteinChip® data manager software.
    Dalmasso EA; Caseñas D
    Methods Mol Biol; 2012; 818():35-48. PubMed ID: 22083814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry.
    Ahmed FE
    J Sep Sci; 2009 Mar; 32(5-6):771-98. PubMed ID: 19219839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
    Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
    Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry is only one piece of the puzzle in clinical proteomics.
    McGuire JN; Overgaard J; Pociot F
    Brief Funct Genomic Proteomic; 2008 Jan; 7(1):74-83. PubMed ID: 18308835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis.
    Novikova SI; He F; Cutrufello NJ; Lidow MS
    Neurobiol Dis; 2006 Jul; 23(1):61-76. PubMed ID: 16549361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.